FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

BACKGROUND: Patients with triple-negative breast cancer (TNBC) expressing the androgen receptor (AR) respond poorly to neoadjuvant chemotherapy, although AR antagonists have shown promising clinical activity, suggesting these tumors are AR-dependent. cAMP responsive element binding protein (CREB)-bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Caligiuri, Maureen, Williams, Grace L., Castro, Jennifer, Battalagine, Linda, Wilker, Erik, Yao, Lili, Schiller, Shawn, Toms, Angela, Li, Ping, Pardo, Eneida, Graves, Bradford, Azofeifa, Joey, Chicas, Agustin, Herbertz, Torsten, Lai, Maria, Basken, Joel, Wood, Kenneth W., Xu, Qunli, Guichard, Sylvie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042772/
https://www.ncbi.nlm.nih.gov/pubmed/36826464
http://dx.doi.org/10.1007/s11523-023-00949-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042772/
https://www.ncbi.nlm.nih.gov/pubmed/36826464
http://dx.doi.org/10.1007/s11523-023-00949-7

Ejemplares similares